Cingulate Inc.CING

$4.99-0.13 (-2.54%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$27M

Micro-cap

-99%

2021 — today

10-Year Price

-100%

2021 — today

52-Week Range

$3.33$11.66

Current $4.99· 20%

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Valuation in context

P/E ratio

-1.0

N/A

Not meaningful — company is unprofitable

P/B ratio

1.4

Historically cheap

Historically cheap relative to the last 10 years

FCF Yield

-73.0%

Below average

Below the 10-year average

Free · No credit card needed

Get alerted when CING is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.